TriSalus Life Sciences Inc

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

TriSalus Life Sciences reports record revenue growth and expands clinical trials

TriSalus Life Sciences demonstrated strong financial performance and operational efficiency in Q2 2024, driven by significant revenue growth and high gross margins.
The company's strategic focus on clinical trials, innovative treatment approaches, and financial flexibility positions it well for future growth and market expansion.
While facing challenges in executing combination therapies and maintaining growth momentum, TriSalus has opportunities to enhance treatment outcomes, diversify its portfolio, and strengthen its market position.

TriSalus Life Sciences reports robust Q3 earnings and strategic growth plans

TriSalus Life Sciences demonstrated strong financial performance in Q3, with significant revenue growth and a focus on cost management.
The company's strategic partnerships and upcoming product launches position it well for market expansion and innovation.
While challenges like expense reduction and achieving profitability exist, TriSalus has opportunities for growth through new product launches and partnerships.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

TriSalus Life Sciences, Inc. is an oncology company, which engages in the business of integrating standard-of-care treatments and investigational immunotherapeutic with disruptive pressure enabled drug delivery infusion systems to transform the treatment paradigm for patients battling liver and pancreatic tumors. The company was founded on September 11, 2020, and is headquartered in Westminster, CO.

TriSalus Life Sciences, Inc. (NASDAQ:TLSI ) Q3 2024 Earnings Conference Call November 14, 2024 9:00 AM ET Company Participants Jim Young - Senior Vice President, Investor Relations & Treasurer Mary Szela - President & Chief Executive Officer Sean Murphy - Chief Financial Officer Conference Call Participants Jason Wittes - ROTH Suraj Kalia - Oppenheimer & Company William Plovanic - Canaccord Genuity Justin Walsh - JonesTrading Operator Good morning, and welcome to TriSalus Science's Third Quarter 2024 Earnings Conference Call. Currently, all participants are in a listen-only mode.

TriSalus Life Sciences, Inc. (TLSI) Q3 2024 Earnings Call Transcript

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences Inc., (Nasdaq: TLSI), an oncology company integrating novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced its financial results for the third quarter ended September 30, 2024, and provided a business update. “We enter the final quarter of 2024 with great momentum, both commercially and clinically, and we are positioned well for an even greater 2025,” stated Mary Szela,.

TriSalus Reports Q3 2024 Financial Results and Provides Business Update

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients suffering from liver cancer through its advanced delivery technology as well as an investigational immunotherapy, nelitolimod, has announced a strategic partnership with Geo-Med, LLC (“Geo-Med”), a certified Service-Disabled Veteran-Owned Small Business (SDVOSB), to expand availability of the TriNav Infusion System (“TriNav”) to U.S.

TriSalus Life Sciences® Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav® Infusion System to U.S. Veterans with Liver Cancer

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. ("TriSalus" or the "Company") (Nasdaq: TLSI), a leader in oncology innovations integrating advanced delivery technology to transform treatment for liver and pancreatic tumors, today announced the launch of the TriNav® LV Infusion System and TriGuide™ Guiding Catheter. These new devices are designed to optimize therapeutic delivery, enhancing treatment options and potentially improving outcomes for patients. Highlights of the Launch: Expanded.

TriSalus Life Sciences Launches TriNav® LV Infusion System and TriGuide™ Guiding Catheters, Expanding Portfolio of PEDD™ Devices for Improved Tumor Treatment

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced delivery technology and novel immunotherapy, nelitolimod, announced today it will host a conference call and webcast on November 14, 2024, at 9:00 a.m. ET to discuss financial results for the third quarter ended September 30, 2024, and provide a business update. A press release detailing the third quarter re.

TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced delivery technology and novel immunotherapy, nelitolimod, announced today that Mary Szela, Chief Executive Officer and President of TriSalus, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Thursday, October 17, 2024. Details for the fireside ch.

TriSalus Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced delivery technology and novel immunotherapy, nelitolimod, has announced the addition of Riad Salem, M.D., to its Scientific Advisory Board (SAB). Dr. Salem is the Chief of Interventional Radiology, and a Professor of Radiology, Surgery, and Medicine in Chicago. Mary Szela, Chief.

TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with standard of care therapies and immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today the publication of research titled, “Intra-arterial Pressure-Enabled Drug Delivery Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model,” in the peer-reviewed Journ.

TriSalus Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With PEDD™ Method via the TriNav® Infusion System

TriSalus Life Sciences, Inc. (NASDAQ:TLSI ) Q2 2024 Earnings Call Transcript August 15, 2024 9:00 AM ET Company Participants Jim Young - SVP, IR and Treasurer Mary Szela - President and CEO Alex Kim - SVP, Interventional Radiology Steven Katz - CMO Sean Murphy - CFO Conference Call Participants Justin Walsh - JonesTrading Operator Good morning, and welcome to TriSalus Science Second Quarter 2024 Earnings Conference Call. Currently, all participants are on listen-only mode.

TriSalus Life Sciences, Inc. (TLSI) Q2 2024 Earnings Call Transcript

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences Inc., (Nasdaq: TLSI), an oncology company integrating novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced its financial results for the second quarter ended June 30, 2024, and provided a business update. Mary Szela, President and Chief Executive Officer of TriSalus Life Sciences, stated, "We concluded the second quarter with robust revenue growth and effective execution.

TriSalus Reports Q2 2024 Financial Results and Business Update

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today it will host a conference call and webcast on August 15, 2024, at 9:00 a.m. ET to discuss financial results for the second quarter ended June 30, 2024, and provide a business update. A press release detailing the second quarter results will be issued prior to t.

TriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference Call

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today the closing of its previously announced exchange offer (the “Offer”) and consent solicitation (the “Consent Solicitation”) relating to its warrants (the “Warrants”) identified in the Prospectus/Offer to Exchange that for.

TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today the expiration and results of its previously announced exchange offer (the “Offer”) and consent solicitation (the “Consent Solicitation”) relating to its warrants (the “Warrants”) identified in the Prospectus/Offer to Ex.

TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants

TriSalus Life Sciences, Inc. is focusing on developing organ-targeted therapy delivery mechanisms and pairing them with their own drugs. Nelitolimod, a TLR9 activator, is showing promising results in various solid tumor contexts, including liver and pancreatic cancers. Despite financial concerns, TriSalus Life Sciences' growing sales and promising clinical data make them a potential bargain investment when considered for the longer term.

TriSalus Life Sciences: Falling Despite Moving Forward Into The Market

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI), an oncology company integrating its novel Pressure Enabled Drug Delivery™ (PEDD™) technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced that data from its Phase 1b PERIO-02 clinical trial was presented in a poster session at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, taking place May 31-June 4, 2024, in Chicago, Illinois. The PEDD approac.

TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today that it has commenced an exchange offer (the “Offer”) and consent solicitation (the “Consent Solicitation”) relating to its warrants (the “Warrants”) identified in the Prospectus/Offer to Exchange (as defined below). The purpose of.

TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants

TriSalus Life Sciences, Inc. (NASDAQ:TLSI ) Q1 2024 Earnings Conference Call May 15, 2024 9:00 AM ET Company Participants Jim Young – Senior Vice President-Investor Relations and Treasurer Mary Szela – President and Chief Executive Officer Sean Murphy – Chief Financial Officer Conference Call Participants Justin Walsh – JonesTrading Operator Good morning. And welcome to TriSalus Life Sciences First Quarter 2024 Earnings Conference Call.

TriSalus Life Sciences, Inc. (TLSI) Q1 2024 Earnings Call Transcript

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences Inc., (Nasdaq: TLSI), today announced its financial results for the first quarter ended March 31, 2024, and provided a business update. “I'm proud to highlight our strong start in the first quarter of 2024 with 116% growth in revenues compared to the first quarter of 2023 and significantly improving our financial position with our debt financing facility with OrbiMed,” said Mary Szela, Chief Executive Officer of TriSalus. “With our recent positive.

TriSalus Reports Q1 2024 Financial Results and Business Update

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today the appointment of Liselotte Hyveled to its Board of Directors. Ms. Hyveled brings over two decades of experience stimulating scientific innovation and advancing pharmaceutical pipelines through research and development excellence. “We are thrilled to welcome Li.

TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today it will host a conference call and webcast on May 15, 2024, at 9:00 a.m. ET to discuss financial results for the first quarter ended March 31, 2024, and provide a business update. A press release detailing the first quarter results will be issued prior to the c.

TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences Inc., (Nasdaq: TLSI), today announced the closing of a debt financing facility for up to $50 million with OrbiMed, a healthcare investment firm. The capital is expected to provide financial flexibility to support the execution of strategic expansion plans and fuel continued growth. Under the terms of the Credit Agreement (the “Credit Agreement”) with OrbiMed, the Company borrowed $25 million at closing. In addition, an aggregate of up to an additi.

TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives

TriSalus Life Sciences, Inc. (TLSI) Q4 2023 Earnings Call Transcript

DENVER & SALT LAKE CITY--(BUSINESS WIRE)--TriSalus Life Sciences Inc., (Nasdaq: TLSI), today announced its financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update. “2023 was a critical year for TriSalus, underscored by significant growth in TriNav revenue, a landmark achievement of permanent reimbursement, and disciplined progress within our technology and clinical pipelines,” said Mary Szela, Chief Executive Officer and President of TriSal.

TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update

DENVER & SALT LAKE CITY--(BUSINESS WIRE)--Technology from TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, was featured in two oral presentations at the Society of Interventional Radiology Annual Scientific Meeting. PERIO-03 Phase 1/1b Update TriSalus is studying an investigational class C toll-like receptor-9 (TLR9) agonist, nelitolimod (formerly SD.

TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today that the Company will present data from recent research findings at the 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting, to be held March 23-28, 2024, in Salt Lake City, Utah. TriSalus will share data on the technical feasibility and saf.

News for TriSalus Life Sciences Inc Stock (TLSI)